title: The histamine H₃ receptor as a therapeutic drug target for metabolic disorders: status, challenges and opportunities.
abstract: Since the histamine-3 receptor (H₃R) was cloned in 1999, huge efforts have been made by most of the key players in the pharmaceutical industry as well as in smaller biotech companies to increase the knowledge on this peculiar receptor, with the ultimate goal of bringing new drugs to the market. This review gives a survey on the most valuable chemical tools discovered so far and the significant pharmacological experiments on metabolic disease models published to date. Pharmacology of H₃R antagonists turns out to be very complex due to various functional activities, species selectivity, presence of H₃R isoforms and the poorly understood dichotomy in efficacy between CNS and metabolic disease models. Adding an extra layer of complexity, researchers have to cope with some recurrent safety concerns, some of them being tightly linked to the nature of the H₃R pharmacophore. Therefore this review also strives to summarize the major hurdles and some of the contradictions seen in the H₃R field, together with a brief overview of the clinical trials currently running.
authors.affiliation: F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Bldg 92/4.18C, CH-4070 Basel, Switzerland. jean-marc.plancher@roche.com
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Plancher
mesh_terms: D015195:Drug Design; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D008659:Metabolic Diseases / Q000188:drug therapy*; D018100:Receptors, Histamine H3 / Q000187:drug effects*
chemical_list: D006633:Histamine Antagonists; D018100:Receptors, Histamine H3